Miruvor
Sign up
The short answer

What studies of prayer and faith healing found

5papers on prayer and faith healing
210people in 1 study testing prayer and faith healing alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: D Little or no difference

Based on the strongest evidence, the randomised trial (very low certainty), for quality of life.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with prayer and faith healing for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 5 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Prayer and faith healing · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Daily life and health overall

Quality of life1 study · 210 people took part in prayer and faith healing Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.

The randomised trial411 randomised · 409 started · 409 analysed · 6 months · 6 months

No clear difference in quality of life.

The evidence is very uncertain about the effect of prayer and faith healing on quality of life in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • No confidence interval shows an important benefit is ruled out
See the 1 study
  1. Effectiveness of distant healing for patients with chronic fatigue syndrome: a randomised controlled partially blinded trial (EUHEALS). (2008)

    People in the study
    411 randomised · 409 started · 409 analysed
    Dose
    6 months
    Outcome
    MHCS (SF-36) Mental Health Component Summary (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Effectiveness of distant healing for patients with chronic fatigue syndrome: a randomised controlled partially blinded trial (EUHEALS).2008 · randomised trial · 411 randomised · 409 started · 409 analysed
    Summary

    This randomised controlled partially blinded trial asked whether distant healing affects people with chronic fatigue syndrome (CFS). Patients were recruited from 14 private practices for environmental medicine in Germany and Austria. In total, 411 patients were invited and agreed to participate, and 409 were analysed. The trial compared immediate distant healing with deferred healing (waiting for 6 months), with some patients blinded to allocation and some knowing it. Distant healing was given for 6 months. The primary measure was the SF-36 Mental Health Component Summary (MHCS); the secondary measure was the Physical Health Component Summary (PHCS). At 6 months there were no differences in post-treatment MHCS between groups. For PHCS the report gives a small non-significant effect from distant healing: 1.11 (95% CI –0.255 to 2.473; p = 0.11). Blinding had a significant effect (p = 0.027): patients who were unblinded became worse, with a mean difference of –1.544 (95% CI –2.913 to –0.176). The report states no relevant interaction for MHCS and PHCS. Thirteen patients withdrew or were lost to follow-up. Side-effect counts were not reported.

  2. Use of alternative treatments by chronic fatigue syndrome discordant twins.2000 · compared with another group · 63 in the study
  3. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
    Summary

    This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.

  4. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.2024 · review
    Summary

    This literature review searched EBSCOhost Academic Search Premier, Proquest, Google Scholar, and the Cochrane Library in June 2022 for published treatments for chronic inflammatory response syndrome (CIRS), ME/CFS, and sick building syndrome. No patients were enrolled by the review; no comparison group, randomization, or follow-up duration was reported. The review reports 13 articles comprising 14 studies on CIRS treatment and also reviews CFS treatment studies. Named CIRS study sizes included 8, 13, 28, 14, 21, 156/111, 20, 35/4, 100, and 68/23. The review states the only treatment with documented clinical efficacy was the Shoemaker Protocol, described in 11 of the 13 articles; table entries list cholestyramine and vasoactive intestinal peptide as successful, while Rea’s antigen intradermal treatments had lack of objective data. CFS studies listed sizes including 49, 1518, 1030, 2036, 62, 409, 101, 171, 33, 32/18, 23, and 218; findings included some benefit for aripiprazole in 101 patients, high frequency of response for low-dose naltrexone in 218, and CBT/GET reported beneficial in six studies but noncurative. Reported side effects include constipation from cholestyramine, hyponatremia from desmopressin, and light-headedness from vasoactive intestinal peptides; medication intolerance was a barrier.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime